Symbiotic Health

Familiar names abound in Center for Biotech awards

By GREGORY ZELLER // Several breakout research projects – and a few familiar faces from the cutting edge – scored funding this week through Stony Brook University’s annual biotechnology awards program. The Center for Biotechnology at SBU, an Empire State Development Division of Science, Technology and Innovation Center for Advanced Technology, has announced the recipients of the 2017-18 Applied Research and Development awards. The awards, along with matching funds from the recipients and other stakeholders,…


Symbiotic Health, Goddard Labs eye Brooklyn move

By GREGORY ZELLER // Two of Long Island’s most-promising biotech startups are packing up their R&D and heading for greener pastures. At least for now. Symbiotic Health and Goddard Labs – both jointly funded by regional business booster Accelerate Long Island and the venture-backed Long Island Emerging Technologies Fund – are gearing up to move to Brooklyn, where affordable, short-term lab space is readily available. Spun out of the Feinstein Institute for Medical Research, Symbiotic…


The Debrief: Noel Goddard, doyenne of detection

No, she’s not related to rocketing pioneer Robert Goddard. Besides a surname, she has nothing in common with former OSI Pharmaceuticals CEO Colin Goddard (though she’s a fan). And her company is not the biz-tech support firm Goddard Labs of Oregon, another common mistake. But as chief executive of Calverton-based biotech enterprise Goddard Labs – where novel molecular diagnostics set the tone – Noel Goddard takes a scientific back seat to no one, and enjoys…


Symbiotoc Health CEO Gerard Honig

Symbiotic Health gets $100K in funding

By GREGORY ZELLER // A spinoff of the Feinstein Institute for Medical Research has snagged a critical $100,000 stake from Accelerate Long Island and the Long Island Emerging Technologies Fund – good news for anyone suffering from the most prevalent hospital-based infection in the United States. Symbiotic Health, which does battle against the insidious Clostridium difficile infection, announced today that Accelerate Long Island has matched the $50,000 investment the LIETF fund made in June –…


Symbiotoc Health CEO Gerard Honig

Leading the fight against C. Diff

By GREGORY ZELLER // Researchers battling the insidious clostridium difficile infection are making progress on several new fronts, including a novel “poop pill” developed by Symbiotic Health, a spinoff from North Shore-LIJ’s Feinstein Institute. C. Diff, as it is known, is the most prevalent hospital-acquired infection in the United States and “an immediate public health threat,” according to the Centers for Disease Control. The infection attacks the gastrointestinal tract when broad-spectrum antibiotics fight off infections but…